



American Cannabis Nurses Association

*Advancing excellence in cannabis nursing practice through advocacy,
collaboration, education, research and policy development*

A Resolution Regarding the Proper Scheduling of Cannabis in the U.S. Controlled Substances Act of 1970 Prepared by the American Cannabis Nurses Association

WHEREAS, cannabis is currently classified as a Schedule I drug according to the U.S. Controlled Substances Act; and,

WHEREAS, uncertainties and injustices are being perpetrated against suffering people by the inappropriate and unjustified Federal Policy of Schedule I placement of cannabis in the Controlled Substances Act; and,

WHEREAS, the recent Committee on the Health Effects of Marijuana of the National Academies of Sciences, Engineering and Medicine concluded that, “There are specific regulatory barriers, including the classification of cannabis as a Schedule I substance, that impeded the advancement of cannabis and cannabinoid research.” and,

WHEREAS, twenty nine states and the District of Columbia currently have laws that allow citizens to legally access cannabis for medical use, and eight of these states and the District of Columbia allow cannabis to be used by adults ‘recreationally’; and,

WHEREAS, cannabis as a natural medicant cannot be classified accurately in any of the existing CSA Schedules; and,

WHEREAS, we believe reclassification of cannabis will improve overall societal health by:

- providing access to safe, accepted and effective medication, and
- allowing municipalities to educate the public about safe cannabis use, and
- reducing the catastrophic personal consequences of incarceration for many citizens, and
- helping to contain the current opioid epidemic in our country and stem the tide of opioid deaths,

THEREFORE BE IT RESOLVED that the American Cannabis Nurses Association calls on the United States Congress to increase the health, safety and well-being of our citizens by establishing a new cannabis-only schedule – Schedule VI – in the Controlled Substances Act that will accommodate all cannabis products.

REFERENCES

- American Civil Liberties Union (2013). Report: The War on Marijuana in Black and White. Retrieved from: <https://www.aclu.org/report/report-war-marijuanablack-and-white>
- Americans For Safe Access (2017). Medical Marijuana Access in the United States, A Patient-Focused Analysis of the Patchwork of State Laws, 2017 Annual Report. Retrieved from http://www.safeaccessnow.org/medical_marijuana_access_in_the_usa
- Bachhuber, M. A., Saloner, B., Cunningham, C. O., Barry, C. L. (2014). Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. *JAMA Internal Medicine*, 174(10), 1668-1673. <http://jamanetwork.com/journals/jamainternalmedicine/fullarticle/1898878>
- Backes, M., (2014). *Cannabis Pharmacy, The Practical Guide to Medical Marijuana*. Black Dog and Leventhal Publishers. New York.
- Boehnke, K.F., Litinas, E., & Clauw, D.J. (2016) Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. *The Journal of Pain*, 17(6), 739-744. doi: <http://dx.doi.org/10.1016/j.jpain.2016.03.002>
- The National Academies of Sciences Engineering and Medicine. (2017, January 5) *The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research*. Washington, DC: The National Academies Press. Retrieved from <http://nationalacademies.org/hmd/reports/2017/health-effects-of-cannabis-and-cannabinoids.aspx>
- Russo, E.B., Grotenhermen, F. (2006). *Handbook of Cannabis Therapeutics: From Bench to Bedside*. The Haworth Press. New York.
- United States Drug Enforcement Administration. (2017). *Drug Schedules*. Washington, DC. Retrieved from <https://www.dea.gov/druginfo/ds.shtml>
- Wakefield, M. A., Loken, B., & Hornik, R. C. (2010). Use of mass media campaigns to change health behaviour. *Lancet*, 376(9748), 1261-1271. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4248563/>